{
    "2020-11-24": [
        [
            {
                "time": "",
                "original_text": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
                "features": {
                    "keywords": [
                        "创新药",
                        "贝达药业",
                        "ALK抑制剂",
                        "恩沙替尼",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医保谈判",
                        "关键阶段",
                        "创新药",
                        "可及性",
                        "提升"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}